554
Participants
Start Date
August 26, 2021
Primary Completion Date
October 1, 2024
Study Completion Date
December 1, 2027
Capox chemotherapy
oxaliplatin: 130 mg/m2 iv d 1, capecitabine: 1000 mg/m2 bid d 1-14, repeated at 3 week intervals
Genecast Biotechnology Co., Ltd, Wuxi
the Third People'S Hospital of Chengdu, Chengdu
West China Hospital, Chengdu
The Third Affiliated Hospital of Kunming Medical University, Kunming
Collaborators (1)
The Third People's Hospital of Chengdu
OTHER
Chengdu Fifth People's Hospital
OTHER
Peking Union Medical College
OTHER
Peking University Cancer Hospital & Institute
OTHER
Sun Yat-sen University
OTHER
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER
Yunnan Cancer Hospital
OTHER
The First Affiliated Hospital of Zhengzhou University
OTHER
The Affiliated Hospital Of Guizhou Medical University
OTHER
Sichuan Provincial People's Hospital
OTHER
Nanchong Central Hospital
OTHER_GOV
Dazhou Central Hospital
OTHER
Leshan People's Hospital
UNKNOWN
GeneCast Biotechnology Co., Ltd.
INDUSTRY
West China Hospital
OTHER